GPS Cancer is a proteogenomic molecular test that helps oncologists guide treatment strategies. It sequences the whole genome of more than 20,000 genes and three billion base pairs, matching against the patient’s normal DNA to help inform personalized treatment strategies.
Asia Genomics, a provider and distributor of molecular testing services in Southeast Asia, will offer the GPS Cancer tool in Singapore, Malaysia, Thailand, Vietnam and the Philippines.
More articles on data analytics & precision medicine:
Yale New Haven Health System integrates ActX Genomic Decision Support in Epic EHR
Wisconsin researchers awarded $5.3M for NIH All of Us program
Chicagoland hospital to offer genetic testing as part of an annual checkup
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
